FibroGen, Inc. (NASDAQ:FGEN) Director Buys $87,500.00 in Stock

FibroGen, Inc. (NASDAQ:FGEN) Director James A. Schoeneck purchased 250,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were purchased at an average cost of $0.35 per share, for a total transaction of $87,500.00. Following the transaction, the director now owns 323,722 shares of the company’s stock, valued at $113,302.70. This trade represents a 339.11 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

FibroGen Stock Up 17.1 %

NASDAQ FGEN opened at $0.37 on Tuesday. FibroGen, Inc. has a 52-week low of $0.18 and a 52-week high of $2.80. The firm has a 50-day moving average price of $0.48 and a 200 day moving average price of $0.43. The stock has a market capitalization of $37.24 million, a P/E ratio of -0.30 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $24.91 million. On average, equities research analysts expect that FibroGen, Inc. will post -0.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of FibroGen in a research note on Tuesday, March 18th. StockNews.com initiated coverage on shares of FibroGen in a research report on Saturday. They issued a “hold” rating on the stock.

Institutional Investors Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC acquired a new position in shares of FibroGen during the 4th quarter worth $27,000. Velan Capital Investment Management LP purchased a new stake in FibroGen during the fourth quarter worth about $42,000. XTX Topco Ltd grew its position in FibroGen by 423.8% during the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 77,693 shares during the period. Franklin Street Advisors Inc. NC increased its holdings in FibroGen by 100.0% in the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 100,000 shares in the last quarter. Finally, FMR LLC lifted its position in shares of FibroGen by 21.8% during the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 68,569 shares during the period. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.